Literature DB >> 31764512

Infantile Myofibromatosis: 32 Patients and Review of Literature.

Guoqiang Zhao1, Ming Zhu, Chaojin Qin, Xiwang Liu, Xufei Zhao.   

Abstract

BACKGROUND: Infantile myofibromatiosis (IM) is a rare benign tumor in the infants, but it has a bad prognosis if IM erncroaches on the viscera. Multiple tissues can be invaded by IM, including the subcutaneous tissue, the muscle of the neck, back, and head, but seldom in the bones and the viscera. The histopathologic and immunohistochemical examinations are necessary in daigonosis of IM as it might be misdiagnosed as the malignant tumor. MATERIALS AND
METHOD: Thirty-two consecutive patients with IM in our hospital (2003-2013) were enrolled and the clinical date were analyzed to understand IM better, such as the feature of clinical manifestations, pathology, imaging tests, and treatment.
RESULTS: All of them underwent excision operations, 4 of them with invasion in the bones, 2 with invasion in the craniums, and the rest in the ulna and the humerus. The immunohistiochemical analysis shown that the tumor cells were positive to vimentin and smooth muscle actin while negative to the S100 protein and desmin. Twenty-five patients were in follow-up, 2 cases recurred.
CONCLUSIONS: IM is a benign tumor, but IM with the viscera involvement has a bad prognosis. The strategy of waiting and observation for IM without visceral involvement could be selected.

Entities:  

Year:  2020        PMID: 31764512     DOI: 10.1097/MPH.0000000000001603

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  2 in total

1.  Avoidance of surgery for head and neck infantile myofibromatosis using imatinib monotherapy.

Authors:  Prasanth Pattisapu; Tara L Wenger; John P Dahl; Randall A Bly; Juliana Bonilla-Velez; Natalie Wu; Anurekha Hall; Erin R Rudzinski; Jonathan A Perkins
Journal:  Clin Case Rep       Date:  2022-02-09

Review 2.  A Primer on a Comprehensive Genetic Approach to Vascular Anomalies.

Authors:  Alexandra J Borst; Taizo A Nakano; Francine Blei; Denise M Adams; Jessica Duis
Journal:  Front Pediatr       Date:  2020-10-19       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.